Novartis seeks next generation of malaria drugs
Determined to eradicate a disease that takes the lives of more than one million people worldwide each year, Novartis has announced it will participate in a new public-private partnership which aims to discover more potent drugs to combat malaria.
The Novartis Institute for Tropical Diseases (NITD) will focus on the development of a one-dose cure for Plasmodium falciparum, the most dangerous form of malaria, and a curative modality for Plasmodium vivax, the most frequent and widely distributed cause of malaria.
